Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial

2020 ◽  
Vol 34 (6) ◽  
pp. 1446-1454 ◽  
Author(s):  
Masoud Nouri‐Vaskeh ◽  
Aida Malek Mahdavi ◽  
Hossein Afshan ◽  
Leila Alizadeh ◽  
Mohammad Zarei
Keyword(s):  
Randomized Controlled Trial ◽  
Liver Cirrhosis ◽  
Disease Severity ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals Impact of Glutathione and Vitamin B-6 in Cirrhosis Patients: A Randomized Controlled Trial and Follow-Up Study

Nutrients ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1978
Author(s):  
Chia-Yu Lai ◽  
Shao-Bin Cheng ◽  
Teng-Yu Lee ◽  
Yung-Fang Hsiao ◽  
Hsiao-Tien Liu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Randomized Controlled Trial ◽  
Liver Cirrhosis ◽  
Disease Severity ◽  
Controlled Trial ◽  
Vitamin B ◽  
Double Blind ◽  
Randomized Controlled ◽  
Antioxidant Capacities

Vitamin B-6 and glutathione (GSH) are antioxidant nutrients, and inadequate vitamin B-6 may indirectly limit glutathione synthesis and further affect the antioxidant capacities. Since liver cirrhosis is often associated with increased oxidative stress and decreased antioxidant capacities, we conducted a double-blind randomized controlled trial to assess the antioxidative effect of vitamin B-6, GSH, or vitamin B-6/GSH combined supplementation in cirrhotic patients. We followed patients after the end of supplementation to evaluate the association of vitamin B-6 and GSH with disease severity. In total, 61 liver cirrhosis patients were randomly assigned to placebo, vitamin B-6 (50 mg pyridoxine/d), GSH (500 mg/d), or B-6 + GSH groups for 12 weeks. After the end of supplementation, the condition of patient’s disease severity was followed until the end of the study. Neither vitamin B-6 nor GSH supplementation had significant effects on indicators of oxidative stress and antioxidant capacities. The median follow-up time was 984 d, and 21 patients were lost to follow-up. High levels of GSH, a high GSH/oxidized GSH ratio, and high GSH-St activity at baseline (Week 0) had a significant effect on low Child–Turcotte–Pugh scores at Week 0, the end of supplementation (Week 12), and the end of follow-up in all patients after adjusting for potential confounders. Although the decreased GSH and its related enzyme activity were associated with the severity of liver cirrhosis, vitamin B-6 and GSH supplementation had no significant effect on reducing oxidative stress and increasing antioxidant capacities.

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial

2014 ◽  
Vol 147 (6) ◽  
pp. 1327-1337.e3 ◽  
Author(s):  
Radha K. Dhiman ◽  
Baldev Rana ◽  
Swastik Agrawal ◽  
Ashish Garg ◽  
Madhu Chopra ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Liver Disease ◽  
Disease Severity ◽  
Controlled Trial ◽  
Randomized Controlled

Effectiveness of 2 Osteopathic Treatment Approaches on Pain, Pressure-Pain Threshold, and Disease Severity in Patients with Fibromyalgia: A Randomized Controlled Trial

2017 ◽  
Vol 25 (2) ◽  
pp. 122-128 ◽  
Author(s):  
Jessica Albers ◽  
Anne Jäkel ◽  
Kai Wellmann ◽  
Ulrike von Hehn ◽  
Tobias Schmidt
Keyword(s):  
Randomized Controlled Trial ◽  
Disease Severity ◽  
Pain Threshold ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Pressure Pain Threshold ◽  
Control Group ◽  
Pressure Pain ◽  
Randomized Controlled ◽  
Osteopathic Treatment

Objective: To assess the effectiveness of osteopathic intervention (OI) and general osteopathic treatment (GOT) in individuals with fibromyalgia syndrome (FMS). Methods: The trial was designed as a randomized controlled trial with 2 osteopathic interventions and 1 untreated control group. The patients in the two osteopathic groups received 10 osteopathic treatments (OI or GOT) within a time period of 12 weeks. The control group did not receive any osteopathic treatment. The primary outcome was the average pain intensity (API) assessed by visual analog scale (VAS). Secondary outcomes were the pressure-pain threshold rated by means of a tender point score, and disease severity, assessed by the Fibromyalgia Impact Questionnaire (FIQ). Results: 50 patients were randomized. The primary outcome parameter API decreased from 7.2 to 4.7 in the OI group, from 6.3 to 4.3 in the GOT group, and increased slightly in the control group from 6.2 to 6.6. There were significant differences for the change in API between the OI group and the control group (VAS: 2.9, 95% confidence interval (CI) = 1.12-4.52), and between the GOT group and the control group (VAS: 2.4, 95% CI = 0.65-4.11), but no significant differences between the OI group and the GOT group. There were no significant differences for the secondary outcome parameters between the groups. Conclusion: A series of osteopathic treatments might be beneficial for patients suffering from FMS.

Sign in / Sign up

Export Citation Format

Share Document